Literature DB >> 22669567

Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Farhad Jadidi-Niaragh1, Mahmood Jeddi-Tehrani, Bita Ansaripour, Seyed Mohsen Razavi, Ramazan Ali Sharifian, Fazel Shokri.   

Abstract

Natural killer T (NKT) cells are a subset of innate immune cells displaying a limited repertoire of antigen specificities and CD1d restriction. Little is known about contribution of NKT cells in cancer initiation and progression. In this study, the frequencies of NKT-like cells, B cells expressing CD1d molecule and CD4(+) regulatory (Treg) cells were analyzed in 40 patients with chronic lymphocytic leukemia (CLL) and 15 healthy subjects by flow cytometry. Our results showed that the frequency of CD3(+)CD56(+) NKT-like cells is significantly decreased in progressive (4.9 ± 0.8 % of total CD3(+) T cells) compared with indolent (8.1 ± 1.2 %, p = 0.036) patients and healthy subjects (10.6 ± 1.7 %, p = 0.003). However, no association was found between NKT-like cell frequency and immunoglobulin heavy chain variable region gene (IGHV) mutation or CD38 and ZAP70 expression. On the other hand, expression of CD1d molecule was significantly higher in leukemic B cells of patients with CLL (75 ± 1.5 % of total CD19(+) B cells) compared to B cells from healthy subjects (59.6 ± 2.2 %, p < 0.001), with no significant difference between progressive and indolent patients. Interestingly, the frequency of Treg cells was inversely correlated with that of NKT-like cells in patients with CLL (r = -0.4, p = 0.002). Our results suggest a protective role for NKT-like cells in patients with CLL, which seems to be downregulated presumably by Treg cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669567     DOI: 10.1007/s12032-012-0262-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  52 in total

1.  Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells.

Authors:  Karin Roelofs-Haarhuis; Xianzhu Wu; Ernst Gleichmann
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 2.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

3.  Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo.

Authors:  Gourapura J Renukaradhya; Venkataraman Sriram; Wenjun Du; Jacquelyn Gervay-Hague; Luc Van Kaer; Randy R Brutkiewicz
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

4.  Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Krzysztof Giannopoulos; Michael Schmitt; Malgorzata Kowal; Paulina Wlasiuk; Agnieszka Bojarska-Junak; Jinfei Chen; Jacek Rolinski; Anna Dmoszynska
Journal:  Oncol Rep       Date:  2008-09       Impact factor: 3.906

5.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; H Sato; E Kondo; M Harada; H Koseki; T Nakayama; Y Tanaka; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features.

Authors:  Sarah E Gibson; Steven H Swerdlow; Raymond E Felgar
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

7.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

8.  Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.

Authors:  Shin-ichiro Fujii; Kanako Shimizu; Virginia Klimek; Matthew D Geller; Stephen D Nimer; Madhav V Dhodapkar
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

Review 9.  The contrasting roles of NKT cells in tumor immunity.

Authors:  Jay A Berzofsky; Masaki Terabe
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

10.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors:  Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

2.  Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.

Authors:  Rupali Das; Peng Guan; Susan J Wiener; Nishant P Patel; Trevor G Gohl; Elizabeth Evans; Maurice Zauderer; Kim E Nichols
Journal:  Blood Adv       Date:  2019-03-12

3.  Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.

Authors:  Robert Weinkove; Collin R Brooks; John M Carter; Ian F Hermans; Franca Ronchese
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 4.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

5.  Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.

Authors:  Farhad Jadidi-Niaragh; Fatemeh Atyabi; Ali Rastegari; Esmail Mollarazi; Melika Kiani; Alireza Razavi; Mehdi Yousefi; Nasim Kheshtchin; Hadi Hassannia; Jamshid Hadjati; Fazel Shokri
Journal:  Tumour Biol       Date:  2016-01-05

Review 6.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17

Review 7.  The role of natural killer T cells in B cell malignancies.

Authors:  Ghasem Ghalamfarsa; Abolghasem Hadinia; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2013-03-19

8.  Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Ali Memarian; Hossein Asgarian-Omran; Seyed Mohsen Razavi; Abdolfattah Sarrafnejad; Fazel Shokri
Journal:  Tumour Biol       Date:  2012-12-27

9.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

10.  Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5(+) B cell expansion.

Authors:  Victoria L Palmer; Vincent K Nganga; Mary E Rothermund; Greg A Perry; Patrick C Swanson
Journal:  BMC Immunol       Date:  2015-11-04       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.